AngioDynamics Port Catheter Lawsuit [December 2025 Update]

November 20th, 2025: Xcela Port Linked to Life-Threatening Infections

A new lawsuit filed in the U.S. District Court for the Southern District of California alleges that design defects in the AngioDynamics Xcela chemo port caused life-threatening infections and disrupted a woman’s breast cancer treatment.

The plaintiff, Daun Reed of Missouri, was implanted with an Xcela Plus Port catheter in December 2018 to support her chemotherapy.

In April 2025, Reed was hospitalized with severe symptoms that quickly escalated to sepsis and Group B strep bacteremia. Within two days, doctors identified her Xcela port as the source of the infection and removed the device.

Testing confirmed strep bacteria on the catheter tip.

According to the complaint, the Xcela port not only endangered Reed’s life but also forced her to stop chemotherapy altogether.

Unwilling to undergo another port implant, Reed had to switch to immunotherapy, altering her breast cancer treatment plan entirely.

The lawsuit claims that AngioDynamics, along with Navilyst Medical Inc. and PFM Medical Inc., knowingly marketed an unreasonably dangerous device.

Similar to prior lawsuits over SmartPort and Vortex devices, Reed’s case highlights recurring allegations that barium sulfate used in the port’s material compromises its structural integrity, causing microfractures, infections, and blood exposure risks over time.

Reed is seeking compensatory and punitive damages under claims including:

• Negligence
• Design and manufacturing defect
• Failure to warn
• Fraudulent concealment
• Breach of warranty
• Violations of the Missouri Merchandising Practices Act

This case joins a growing number of product liability suits filed against AngioDynamics and other port catheter manufacturers, as plaintiffs across the country continue to report serious complications.

November 12th, 2025: Blood Clot Complications Lead to Wrongful Death Claim

A newly filed lawsuit accuses AngioDynamics and its subsidiary Navilyst Medical of knowingly placing patients at risk by failing to address serious design and manufacturing flaws in its SmartPort catheter system.

The complaint was brought by the widow of the victim, who died after suffering severe thrombosis complications allegedly caused by the defective device.

The victim received a SmartPort CT Single Titanium Port System in February 2023 to facilitate chemotherapy for lung cancer.

Just five months later, he was hospitalized with acute thrombosis, where doctors identified two blood clots linked directly to the implanted port.

Despite efforts to treat the condition, Ballew’s health rapidly declined, and he passed away on October 3, 2025.

According to the lawsuit, the SmartPort’s flawed design and material composition were directly responsible for his injuries.

Specifically, the complaint points to the use of barium sulfate in the catheter material, which plaintiffs allege weakens the structural integrity of the device.

This makes the ports brittle over time, leading to microfractures, blood clots, device migration, and potentially fatal complications.

The lawsuit further alleges that AngioDynamics and Navilyst had received hundreds of adverse event reports from other patients experiencing similar complications.

However, the companies failed to issue warnings, update safety labels, or conduct a recall,  allowing the defective product to remain on the market.

The complaint outlines multiple legal claims, including:

• Design and manufacturing defect
• Failure to warn
• NegligenceBreach of warranty
• Fraudulent concealment
• Violations of the Oklahoma Consumer Protection Act
• Wrongful death and survival action

The plaintiff is seeking both compensatory and punitive damages, arguing that the device “contained manufacturing defects when it left the Defendants’ possession,” and that these defects created “an unreasonably dangerous risk of injury.”

November 3rd, 2025: November 2025 JPML Update

Case filings in the AngioDynamics port catheter lawsuit increased slightly between October and November, rising from 248 to 252.

This MDL focuses on alleged defects in implantable port devices used for long-term medication delivery.

Plaintiffs claim the catheters can fracture or degrade inside the body, leading to serious health risks.

The ongoing case growth suggests continued scrutiny of device safety and manufacturer responsibility.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

October 28th, 2025: Bellwether Trial Process Advances in AngioDynamics Port Catheter Lawsuits

A coordinated case management plan has been approved for the growing number of lawsuits involving AngioDynamics port catheter injuries.

Plaintiffs allege that the company’s implanted port systems, used to deliver chemotherapy and other intravenous treatments, were defectively designed and caused severe injuries, including catheter fractures, infections, device migration, and thrombosis.

There are currently at least 128 lawsuits pending in federal court over AngioDynamics’ SmartPort, Vortex Port, Xcela Port, and similar products.

All federal claims have been consolidated under U.S. District Judge Jinsook Ohta in the Southern District of California.

To move the litigation forward, Judge Ohta has outlined a bellwether selection process.

These early test trials will evaluate how juries respond to the most common injury types alleged in the litigation: infections, device fractures, and thrombosis.

Key dates in the selection timeline include:

• February 6, 2026: Parties meet to determine injury-type distribution across test cases
• June 5, 2026: Each side selects 9 cases, forming a pool of 18 lawsuits
• July 15, 2026: Plaintiff Fact Sheets due for all selected cases
• September 1, 2026: Defendant Fact Sheets due
• December 11, 2026: Each party strikes one case from the opposing side’s list to finalize a pool of 8 bellwether trials

These cases will go through additional discovery, expert depositions, and potentially trial preparation.

While the outcomes will not be binding on other plaintiffs, the bellwether results may shape future settlement negotiations or guide broader litigation strategy.

This MDL mirrors the structure of the Bard PowerPort litigation, which involves nearly 2,000 similar claims over catheter design failures.

As in that case, AngioDynamics plaintiffs argue that port failures were not isolated events but stemmed from systemic design flaws.

If no global settlement is reached after the bellwether trials, Judge Ohta may remand individual cases to their original jurisdictions for trial.

However, this multi-year process will help determine the value and viability of these claims going forward.

October 14th, 2025: AngioDynamics Port Catheter Lawsuits Advance Toward Bellwether Trials Amid New Injury Claims

The federal litigation over AngioDynamics port catheters is expanding as plaintiffs and defendants prepare to select the first bellwether cases in the Southern District of California before Judge Jinsook Ohta.

More than 130 lawsuits allege that devices such as the SmartPort, Vortex Port, and Xcela Port were defectively designed, causing fractures, infections, migration, and blood clots that often require surgery.

One plaintiff from Kentucky says her SmartPort failed within months of implantation, leaving her permanently injured.

Her suit accuses the manufacturer of ignoring years of fracture reports and failing to warn doctors of known risks.

The court’s plan calls for narrowing 18 candidate cases to eight bellwether trials by December 2026, focusing on the most common injuries.

These early trials will help shape settlement negotiations and test key evidence that could impact hundreds of similar claims nationwide.

October 9th, 2025: Bellwether Trial Selection Begins in AngioDynamics Port Catheter Litigation

Lawyers representing both sides in the AngioDynamics port catheter MDL have outlined a plan to select 18 bellwether cases by June 2026.

These early test trials will focus on three key injuries: port catheter infections, device fractures, and thrombosis, which are among the most common and serious complications reported by plaintiffs.

Currently, at least 128 lawsuits have been filed against AngioDynamics over alleged defects in port catheter implants like the SmartPort, Vortex Port, and Xcela Port, devices often used during chemotherapy or other long-term IV treatments.

Plaintiffs claim the implants are prone to fracture, migrate, cause infection, or lead to dangerous blood clots, often requiring corrective surgery.

All federal lawsuits have been consolidated under Judge Jinsook Ohta in the Southern District of California for coordinated pretrial proceedings.

This centralization mirrors the structure of a separate MDL against Bard PowerPort, which faces similar allegations.

By December 2026, the initial pool of 18 bellwether cases will be narrowed down to eight, with trials not expected to begin until early 2028.

The outcomes of these early trials will not be binding but are likely to influence future settlement discussions and trial strategies.

As the litigation grows, these bellwether cases will serve as a crucial test of how juries respond to the evidence and expert testimony surrounding port catheter safety.

October 1st, 2025: October 2025 JPML Update

The AngioDynamics port catheter lawsuit saw a rise in claims between September and October, increasing from 218 to 248 total cases.

The litigation centers around allegations that the company’s implantable port catheter devices were defectively designed, leading to catheter fractures, migration, and severe internal injuries.

This steady climb in case volume reflects continued awareness and legal action among individuals who have experienced complications.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

September 22nd, 2025: Selection Process for Early Trial Cases Underway

More than 200 lawsuits have been filed in federal court alleging that AngioDynamics’ implantable port catheters were defectively designed and caused serious injuries,

The injuries include catheter fracture, migration, infection, and vascular damage.

The lawsuits are centralized before U.S. District Judge Jinsook Ohta in the Southern District of California as part of a federal multidistrict litigation (MDL), aimed at coordinating discovery and streamlining proceedings.

On September 16, Judge Ohta issued a directive requiring both parties to submit a joint proposal by September 24, 2025, outlining how a small group of bellwether cases should be selected for early trial preparation.

These bellwether trials are not binding but will serve as test cases to help assess jury responses to common evidence and may play a key role in shaping future settlement discussions.

At the heart of the litigation are claims that barium sulfate used in the catheter material degrades over time, weakening the devices and making them prone to fracture, migration, and life-threatening complications.

This litigation is similar to the Bard PowerPort Lawsuit, as both these devices are claimed to be defective based on the presence of barium sulfate in the catheter material.

September 10th, 2025: Family Sues AngioDynamics Over Allegedly Defective SmartPort Catheter

A wrongful death lawsuit has been filed in California federal court against AngioDynamics Inc., alleging that its SmartPort vascular access device caused the death of a Florida man due to severe complications including sepsis.

According to the complaint, the decedent, John Verkis, received the SmartPort in May 2021 to facilitate medication delivery.

By October 2022, Verkis reported severe chest pain, was hospitalized, and diagnosed with sepsis. He died the following month.

The suit claims the SmartPort catheter, made of silicone or polyethylene mixed with barium sulfate, degrades over time.

This degradation allegedly causes microfractures, material instability, and increased susceptibility to infection, catheter migration, and vessel perforation.

The SmartPort was introduced under FDA 510(k) clearance for a different device, the Triumph VTX Port with LiveValve Catheter, originally developed by Horizon Medical Products.

The plaintiff argues that despite significant design differences, AngioDynamics claimed the two devices were substantially equivalent, making the SmartPort misbranded under federal law.

Additionally, the suit alleges that AngioDynamics received a large volume of adverse event reports, including device fractures and vascular perforations, yet failed to properly disclose the severity or frequency of complications to consumers or healthcare providers.

The lawsuit brings claims for:

• Negligence
• Failure to Warn
• Design Defect

The case is Carter v. Angiodynamic Inc. et al., No. 3:25-cv-2248, pending in the U.S. District Court for the Southern District of Florida.

AngioDynamics has not yet commented publicly on the case.

September 2, 2025: September 2025 JPML Update

The number of pending AngioDynamics lawsuits increased in September, rising to 218 cases compared to 208 cases in August.

These lawsuits involve claims that certain AngioDynamics medical devices caused serious injuries due to alleged defects in their design and manufacture.

As more individuals come forward, the litigation continues to progress with pretrial proceedings focused on evidence gathering and case coordination.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

August 18th, 2025: Infection Risks from Defective Design in AngioDynamics Port Catheter

Lawsuits are growing against AngioDynamics over its implantable port catheter systems, with plaintiffs alleging that defective designs and materials have caused dangerous infections, blood clots, and other severe injuries.

AngioDynamics ports, including models like the SmartPort and Xcela Plus, are intended to provide long-term vascular access for patients undergoing treatments such as chemotherapy.

However, claims indicate the polyurethane and barium sulfate blend used in these devices can degrade over time, causing cracks and surface roughness that trap bacteria and promote biofilm formation, leading to catheter-related bloodstream infections and potentially life-threatening complications.

As of August 2025, at least 208 lawsuits have been centralized in the Southern District of California as part of MDL No. 3125. U.S. District Judge Jinsook Ohta is overseeing the litigation, which is currently in early pretrial stages.

A plaintiff leadership committee has been appointed, and a bellwether trial schedule is expected to follow.

Plaintiffs allege that AngioDynamics failed to use safer alternative materials—such as SMA-coated catheters known to resist bacterial colonization—and did not adequately warn patients or healthcare providers of the infection risks.

No recalls have been issued to date for the port devices named in the litigation.

August 1st, 2025: August 2025 JPML Update

The AngioDynamics port catheter MDL added 28 cases between July and August, increasing the total to 208.

This marks the highest monthly rise in the litigation to date.

Plaintiffs continue to allege catheter fractures and migration, prompting increased scrutiny of device design and long-term safety.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

July 24th, 2025: AngioDynamics SmartPort Lawsuits Centralized in MDL Over Pulmonary Embolism and Catheter Fracture Risks

A growing number of product liability lawsuits involving AngioDynamics’ SmartPort implantable port catheter have been consolidated in a federal multidistrict litigation (MDL) in the Southern District of California.

The lawsuits allege that defects in the device have led to serious complications, including pulmonary embolism, catheter fracture, and bloodstream infections.

As of mid-2025, approximately 180 cases have been transferred to MDL No. 3125, overseen by U.S. District Judge Jinsook Ohta.

Plaintiffs claim that the SmartPort (used to deliver medications such as chemotherapy) was defectively manufactured using barium sulfate-infused polyurethane, which allegedly weakens over time and causes microfractures.

These fractures can result in device migration, embolization, or infection.

On March 4, 2025, AngioDynamics and its subsidiary Navilyst Medical filed a motion seeking dismissal of 58 lawsuits, arguing a lack of sufficient product identification. 

Plaintiffs’ attorneys have pushed back, asserting that the devices were widely used and marketed under the same design specifications.

Many complaints cite pulmonary embolism and catheter migration as key injuries, with some cases requiring emergency surgical intervention to retrieve fractured components.

Others allege chronic infection or sepsis linked to port degradation.

AngioDynamics has not issued a recall, but litigation continues to highlight safety concerns with long-term use of the SmartPort device.

No bellwether trials have yet been scheduled.

Pretrial proceedings in the MDL are expected to focus on general causation and product design defects.

July 15th, 2025: Barium Sulfate at Center of Design Defect Claims

AngioDynamics port catheters, including SmartPort devices, use barium sulfate to provide visibility under fluoroscopy and other imaging techniques.

Plaintiffs allege that in these devices, barium sulfate is inadequately bonded to the silicone or polyurethane matrix, leading to a gradual leaching of particles into surrounding tissues and fluids.

This leaching process results in surface pitting, where microvoids appear in the device material.

These irregular surfaces not only weaken the catheter wall, making it prone to cracking or breaking, but also allow bacterial adhesion, increasing the likelihood of bloodstream infections.

Over time, repeated mechanical strain (especially during use for chemotherapy or high-pressure injections) can cause catheter fragmentation, with pieces entering the bloodstream or migrating to the heart or lungs.

MDL No. 3125 includes claims that AngioDynamics knew of safer alternatives and did not disclose the long-term risks posed by uncoated barium sulfate and the resulting structural degradation of their port devices.

July 11, 2025: AngioDynamics Port Catheter Lawsuit Filed After Device Fractures in Patient’s Heart

A new lawsuit has been filed against AngioDynamics, Inc. and Navilyst Medical, Inc. after a Florida woman’s implanted SmartPort catheter fractured and migrated into her heart, allegedly resulting in emergency surgery and serious injury.

The complaint, filed by the woman’s son on behalf of her estate, was brought in the U.S. District Court for the Southern District of California.

According to the lawsuit, the plaintiff received an AngioDynamics SmartPort device on June 10, 2021.

Less than a month later, the port fractured, and multiple pieces were found in her right ventricle.

Emergency procedures were conducted on July 7 and 8 to retrieve the fragments and remove the remaining device.

The plaintiff alleges the SmartPort was defectively designed due to its use of barium sulfate, a compound that may degrade and contribute to structural failure.

The lawsuit claims the manufacturers were aware (or should have been aware) of the device’s potential to fracture, but failed to provide adequate warnings to healthcare providers or patients.

This case joins over 160 similar lawsuits currently centralized in multidistrict litigation (MDL No. 3125) before Judge Jinsook Ohta in the Southern District of California.

The MDL consolidates claims that AngioDynamics’ port catheter devices, including the SmartPort, are prone to fracture and migration, resulting in internal injuries, infections, and in some cases, emergency surgical intervention.

Coordinated pretrial proceedings are ongoing. Bellwether trials may be scheduled to help evaluate liability and damages issues that could affect the broader litigation.

July 1st, 2025: July 2025 JPML Update

The AngioDynamics port catheter MDL added 18 new cases between June and July, increasing the total from 162 to 180.

This marks the largest month-over-month growth in the litigation.

Plaintiffs continue to allege that defects in the design of AngioDynamics’ implantable ports have led to fracturing, migration, and serious internal injuries.

Pretrial proceedings remain in early stages, with initial discovery and scheduling orders expected to shape the next phase of the litigation.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

June 16th, 2025: Industry-Funded Study Prompts Scrutiny Amid Growing Lawsuits

A new peer-reviewed study, partly funded by AngioDynamics and other central venous access device (CVAD) manufacturers, is raising eyebrows as lawsuits mount against the company over its port catheter systems.

The study, published in the American Journal of Infection Control, prioritized future clinical trials to address infection risks tied to implantable port devices—such as those at the center of ongoing litigation against AngioDynamics

The research, conducted by a coalition of global medical experts, highlighted critical areas for investigation, including catheter securement methods, disinfection protocols, and vascular access team practices.

This comes as AngioDynamics and its subsidiary, Navilyst Medical, face over 150 lawsuits nationwide.

Plaintiffs claim that the companies’ implantable port catheters—used to deliver chemotherapy and other intravenous treatments—are defectively designed and prone to fracturing.

Reports describe broken catheter pieces migrating through the body, sometimes into the heart, requiring emergency surgery and leaving lasting harm or disfigurement.

Allegations in these lawsuits include design defect, failure to warn, negligence, and breach of warranty.

Central to the litigation is the use of barium sulfate in the catheter materials, which plaintiffs argue degrades over time and weakens the device’s structural integrity.

June 2nd, 2025: June 2025 JPML Update

No new cases were added to the AngioDynamics MDL in the past month.

The total remains at 162 cases, a pause in new filings during this period.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

A new AngioDynamics SmartPort lawsuit filed on May 7 in the U.S. District Court for the Northern District of California alleges the implant fractured inside the plaintiff’s body, resulting in emergency surgery.

The plaintiff in the suit claims her AngioDynamics SmartPort catheter shattered and migrated to her heart, requiring surgical intervention to retrieve the fractured pieces.

The plaintiff was implanted with the SmartPort in April 2011, but during removal in August 2017, physicians discovered the catheter had broken apart and lodged debris in her right atrium.

The lawsuit alleges the SmartPort’s polymer-based catheter, which contains barium sulfate, was defectively designed, compromising its structural integrity over time.

The plaintiff claims she was unaware until 2023 that the catheter’s failure may have stemmed from defective materials and manufacturing flaws, including fissures and cracks caused by the polymer’s chemical composition.

AngioDynamics now faces more than 150 SmartPort and port catheter lawsuits nationwide, each alleging that the use of barium sulfate in the device’s construction contributes to product degradation, catheter fractures, infection, and delayed treatment.

The plaintiff asserts that AngioDynamics and co-defendant Navilyst Medical marketed the SmartPort as safe despite knowledge of potential device failure risks.

The lawsuit includes claims of negligence, failure to warn, defective design, breach of warranty, and fraudulent concealment under Illinois law.

Patients who suffered similar injuries may be eligible to file an AngioDynamics SmartPort lawsuit and should consult a port catheter lawyer to discuss their legal options.

The AngioDynamics Port Catheter Lawsuit involves claims that the implanted device, used for long-term venous access, has caused serious complications such as infections, fractures, and blood clots.

Plaintiffs allege that AngioDynamics and Navilyst Medical failed to warn patients and healthcare providers about these risks.

11 cases have been added to the AngioDynamics MDL in the past month.

This growth has been consistent throughout this year, with 62 cases added to the litigation since January 1st.

These complications can result in significant medical issues requiring surgical intervention and long-term care.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

The AngioDynamics Port Catheter Lawsuit saw a slight change in filings between March and April 2025.

In March, there were 120 total new cases filed, with 24 new claims introduced into the multidistrict litigation.

By April, the number of filings increased to 141, reflecting a rise of 21 new cases.

This modest increase is a steady continuation of the litigation process, with individuals who have experienced harm from AngioDynamics and Navilyst Medical port catheters continuing to seek legal recourse.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

The AngioDynamics Port Catheter Lawsuit is ongoing. 

A Florida woman has filed a lawsuit against AngioDynamics, claiming its SmartPort port catheter caused an E. coli infection that led to hospitalization and surgical removal of the device.

Jessica Malagon, who received a SmartPort in June 2020 for chemotherapy, developed an infection in April 2021 and was later diagnosed with an infected port in March 2023.

She underwent surgery to remove it in December 2023.

The lawsuit alleges the device’s defective design, particularly its use of barium sulfate, made it prone to microfractures and infections.

This case joins a growing number of AngioDynamics Port Catheter Lawsuits centralized in multidistrict litigation (MDL) in California under U.S. District Judge Jinsook Ohta.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

As of March 2025, the AngioDynamics litigation has seen significant developments, particularly with the Judicial Panel on Multidistrict Litigation (JPML) overseeing the consolidation process.

The JPML has moved forward with creating a centralized multidistrict litigation (MDL), aiming to streamline and expedite the handling of the growing number of cases related to defective medical devices, such as AngioDynamics’ vascular access ports.

In February 2025, the number of cases was relatively lower, with only six new lawsuits added to the MDL.

However, by March 2025, there has been an increase, with 24 new cases joining the litigation.

This surge indicates a growing recognition of the potential risks associated with the devices and highlights the ongoing efforts to ensure victims receive fair compensation.

The AngioDynamics litigation involves legal action against the company over allegations related to its medical devices, including issues with product safety and effectiveness.

Plaintiffs claim that the devices, such as the AngioDynamics’ vascular access ports, were defectively designed, leading to severe complications and adverse health effects.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

The AngioDynamics Port Catheter Lawsuit is ongoing. 

AngioDynamics is moving to dismiss 58 of the 125 port catheter lawsuits consolidated in multidistrict litigation (MDL) before U.S. District Judge Jinsook Ohta in California.

The company argues these cases were filed beyond state-specific statutes of limitations, with some plaintiffs waiting up to 22 years to sue.

The lawsuits claim AngioDynamics’ chemo port catheters, including the SmartPort and Vortex, were defectively designed, leading to infections, fractures, and migration.

Plaintiffs argue the company concealed these risks, delaying their ability to file.

Despite this motion, the litigation is expected to grow, and Judge Ohta is likely to establish bellwether trials to help guide potential settlements.

If no resolution is reached, cases may proceed to individual trials.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

The AngioDynamics Port Catheter Lawsuit is ongoing. 

AngioDynamics port catheters, commonly used for long-term venous access in chemotherapy and medical treatments, can pose a serious risk of central line infections.

These infections occur when bacteria enter the bloodstream through the catheter, potentially leading to life-threatening complications.

Types of Central Line Infections

1. Local Infection – Occurs at the catheter insertion site, causing redness, swelling, pain, or drainage.
2. Systemic Infection (Bacteremia) – When bacteria enter the bloodstream, leading to fever, chills, rapid heartbeat, confusion, and severe illness.

Risk Factors for Infection

• Extended catheter use
• Frequent blood draws or medication infusions
• Weakened immune system
• Central line placement in higher-risk areas like the neck or groin

Preventing Infections in Port Catheters

• To reduce infection risk, hospitals follow strict protocols, including:
• Hand hygiene before touching the line
• Sterile placement techniques and antimicrobial coatings
• Routine cleaning with antiseptic solutions
• Minimizing catheter use when possible

Treatment for Infections

Patients with central line infections may require:

• Antibiotics to fight bacteria
• Catheter removal if the infection is severe
• Flushing the line with high-dose antibiotics in some cases

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

The AngioDynamics Port Catheter Lawsuit is ongoing. 

A new lawsuit has been filed against AngioDynamics and Navilyst Medical on behalf of a deceased Virginia woman, alleging her Vortex port catheter led to a severe infection that required surgical removal.

The lawsuit claims manufacturers failed to warn the public about the high failure rates of AngioDynamics port catheters, leading to dangerous complications.

Filed on February 6, the lawsuit joins a growing number of cases centralized in multidistrict litigation (MDL) in the Southern District of California.

Plaintiffs argue that the Vortex port was defectively designed, making it prone to degradation, migration, and infections.

As more cases are consolidated, Judge Jinsook Ohta is expected to establish bellwether trials, which will serve as test cases to evaluate how juries respond to key evidence.

While these early trials will not be binding, they could influence potential settlements or lead to individual trials if no resolution is reached.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

The AngioDynamics Port Catheter Lawsuit is ongoing. 

A new case management order has authorized plaintiffs to directly file lawsuits against AngioDynamics in the U.S. District Court for the Southern District of California, where federal cases involving defective port catheters are consolidated in multidistrict litigation (MDL).

This direct filing process is expected to streamline litigation by avoiding delays caused by case transfers from other courts.

Plaintiffs allege the port catheters were defectively designed, leading to fractures, infections, and device migration inside patients’ bodies.

With over 90 lawsuits already filed, legal experts anticipate significant growth in claims throughout 2025.

As litigation progresses, Judge Jinsook Ohta, is expected to establish bellwether trials, which will serve as early test cases to gauge how juries respond to key evidence.

While bellwether trial outcomes will not be binding, they help facilitate global settlements or lead to individual cases being sent back for trial in their original districts.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.

The AngioDynamics Port Catheter Lawsuit is ongoing. 

The AngioDynamics Port Catheter lawsuit involves claims that the device, used for long-term venous access, has caused complications such as infections, device fractures, and blood clots. Plaintiffs allege that AngioDynamics failed to adequately warn users of these risks.

In December, 72 cases were pending in the AngioDynamics Port MDL.

The number of cases pending has increased to 90 in January 2025, with 18 new claims added.

This growth reflects increasing awareness of the health issues linked to the AngioDynamics Port Catheter.

Complications associated with the device can lead to severe medical challenges, requiring interventions and affecting patients’ quality of life.

If you or a loved one experienced severe complications such as blood clots, infections, or catheter fractures requiring surgery due to a defective AngioDynamics port catheter, you may be eligible to file an AngioDynamics Port Catheter Lawsuit and seek compensation.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify for the AngioDynamics Port Catheter Lawsuit instantly.